Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6020787 | Journal of Neuroimmunology | 2012 | 9 Pages |
Abstract
We examined the role of Notch ligand Delta-like 1 (Delta1) in the development of Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease (TMEV-IDD). Blocking of Delta1 by anti-Delta1 monoclonal antibody (mAb) in the effector phase significantly suppressed the disease development of TMEV-IDD both clinically and histologically. The number of infiltrating inflammatory mononuclear cells in the spinal cords was also decreased in mice treated with anti-Delta1 mAb at the effector phase. Flow cytometric analysis of cytokine staining revealed that IFN-γ- or IL-4-producing CD4+ splenocytes were significantly decreased in mice treated with anti-Delta1 mAb in the spleens, whereas IL-10-producing CD4+ splenocytes were increased. Furthermore, IFN-γ-, TNF-α-, IL-4-, or IL-10-producing CD4+ cells were decreased in spinal cords, and IL-17-producing CD4+ cells were increased. These data suggest that Delta1 may play important roles in the development of TMEV-IDD and that antibodies to Delta1 could be used as a novel therapeutic treatment of demyelinating diseases such as human multiple sclerosis.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sayaka Tsugane, Sho Takizawa, Tomoki Kaneyama, Motoki Ichikawa, Hideo Yagita, Byung S. Kim, Chang-Sung Koh,